Tenderwize
Back to tender search

Non-exclusive discount agreement for Zolmitriptan (ATC N02CC03)

AOK Niedersachsen. Die Gesundheitskasse.·Hannover, Germany·Deadline Mar 27, 2027 · 214 days left·Open·Supplies·Framework
Structured notice only
Original notice title

Germany – Pharmaceutical products – Abschluss eines nicht exklusiven Rabattvertrages nach § 130a Abs. 8 SGB V zu Arzneimitteln mit dem Wirkstoff Zolmitriptan (ATC N02CC03).

50/100

Opportunity Score

Needs reviewLow complexity
SuppliesFrameworkOpen
Why this score?

Opportunity

50 / 100

Complexity

20 / 100

Risk factors

Open-house contracts will be automatically terminated when exclusive discount agreements are awarded. This can happen a...

Electronic submission is not allowed; only paper submission is accepted. This increases administrative burden and risk...

No procurement documents available

Deep Portfolio Analysis

Deep Company Fit Analysis

Uses:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Overview

Moderate opportunity

Key Facts

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until May 2027
  • Conclusion of non-exclusive discount agreements for pharmaceutical products with active substance Zolmitriptan (ATC N02CC03)
  • Open-house model: all interested and eligible pharmaceutical companies may participate without selection
Show full summary

This is a non-exclusive discount agreement ('open-house model') under § 130a Abs. 8 SGB V for pharmaceuticals containing Zolmitriptan (ATC N02CC03). The AOK Niedersachsen invites all interested pharmaceutical companies to conclude discount agreements without a competitive selection. The agreement period runs from 01 June 2025 to 31 May 2027, with contracts possible at any time during this period. The open-house agreements will be replaced automatically when exclusive discount contracts are awarded (expected 6-8 months after publication of a call for competition). The procedure is not a public contract under EU procurement law; the publication is for transparency purposes. Submission deadlines apply for initial contracts (24 April 2025) and later for monthly join dates. Electronic submission is not allowed; paper submission is required.

Risks

Open-house contracts will be automatically terminated when exclusive discount agreements are awarded. This can happen a...

Electronic submission is not allowed; only paper submission is accepted. This increases administrative burden and risk...

No procurement documents available

Analysis may be incomplete

Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.

Key Requirements

Technical

  • Must be a pharmaceutical entrepreneur within the meaning of § 4 Abs. 18 AMG or a consortium of such
  • Pharmaceutical products must be authorised for market in Germany under AMG
  • The pharmaceutical entrepreneur must have its registered office within Germany, EU, or EEA (§ 9 Abs. 2 Satz 1 AMG)

Requirements may be incomplete.

Award Criteria

Lot 1

Price (discount) criterion; uniform conditions apply to all participants.

Buyer

Location

Hannover, DEU

Identifier

AOK- Niedersachsen. Die Gesundheitskasse

Activity

Health

Lots (1)

LOT-0000

Non-exclusive discount agreement for Zolmitriptan (ATC N02CC03)

Open-house model for Zolmitriptan (ATC N02CC03) discount agreements. All eligible pharmaceutical companies may join under uniform conditions. Contracts are non-exclusive and will be replaced by exclusive agreements once awarded.

SuppliesFrameworkEU fundedElectronic submission

Location

DE929, Germany

Duration

May 2025 - May 2027

Category

Pharmaceutical products

Award Criteria

Price

Deadline

Deadline Mar 27, 2027

Procurement Details

Publication date
31 Mar 2025
Languages
German

Reference metadata

Legal basis
32014L0024

Reference IDs

Tender ID
207292-2025

Similar tenders